Literature DB >> 15008983

Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease.

N W Savage1, K Barnard, P J Shirlaw, D Rahman, M Mistry, M P Escudier, J D Sanderson, S J Challacombe.   

Abstract

Orofacial granulomatosis (OFG) is a condition of unknown aetiology with histological and, in some cases, clinical association with Crohn's disease (CD). However, the exact relationship between OFG and CD remains uncertain. The aim of this study was to determine whether OFG could be distinguished immunologically from CD by comparing non-specific and specific aspects of humoral immunity in serum, whole saliva and parotid saliva in three groups of patients: (a) OFG only (n = 14), (b) those with both oral and gut CD (OFG + CD) (n = 12) and (c) CD without oral involvement (n = 22) and in healthy controls (n = 29). Non-specific immunoglobulin (IgA, SigA, IgA subclasses and IgG) levels and antibodies to whole cells of Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans were assayed by enzyme-linked immunosorbent assay (ELISA) in serum, whole saliva and parotid saliva. Serum IgA and IgA1 and IgA2 subclasses were raised in all patient groups (P < 0.01). Salivary IgA (and IgG) levels were raised in OFG and OFG + CD (P < 0.01) but not in the CD group. Parotid IgA was also raised in OFG and OFG + CD but not in CD. The findings suggest that serum IgA changes reflect mucosal inflammation anywhere in the GI tract but that salivary IgA changes reflect involvement of the oral cavity. Furthermore, the elevated levels of IgA in parotid saliva suggest involvement of the salivary glands in OFG. Serum IgA antibodies to S. cerevisiae were raised markedly in the two groups with gut disease while serum IgA (or IgG) antibodies to C. albicans were elevated significantly in all three patient groups (P < 0.02). No differences were found with antibodies to S. mutans. Whole saliva IgA antibodies to S. cerevisiae (and C. albicans) were raised in the groups with oral involvement. These findings suggest that raised serum IgA antibodies to S. cerevisiae may reflect gut inflammation while raised SIgA antibodies to S. cerevisiae or raised IgA or IgA2 levels in saliva reflect oral but not gut disease. Analysis of salivary IgA and IgA antibodies to S. cerevisiae as well as serum antibodies in patients presenting with OFG may allow prediction of gut involvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008983      PMCID: PMC1808974          DOI: 10.1111/j.1365-2249.2004.02394.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.

Authors:  E Lindberg; K E Magnusson; C Tysk; G Järnerot
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Antibodies to mycobacterial stress protein in patients with orofacial granulomatosis.

Authors:  L Ivanyi; A Kirby; J M Zakrzewska
Journal:  J Oral Pathol Med       Date:  1993-08       Impact factor: 4.253

3.  Role of recurrent oral candidiasis associated with lingua plicata in the Melkersson-Rosenthal syndrome.

Authors:  M Miyashita; S Baba; H Suzuki
Journal:  Br J Dermatol       Date:  1995-02       Impact factor: 9.302

4.  Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis.

Authors:  S A Naser; K Hulten; I Shafran; D Y Graham; F A El-Zaatari
Journal:  Vet Microbiol       Date:  2000-12-20       Impact factor: 3.293

5.  The clinical entity of orofacial Crohn's disease.

Authors:  A J Williams; D Wray; A Ferguson
Journal:  Q J Med       Date:  1991-05

6.  In vitro human lymphocyte proliferative responses to a glycoprotein of the yeast Saccharomyces cerevisiae.

Authors:  C J Darroch; S E Christmas; R M Barnes
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

7.  Mucosal cell-mediated immunity to mycobacterial, enterobacterial and other microbial antigens in inflammatory bowel disease.

Authors:  J P Ibbotson; J R Lowes; H Chahal; J S Gaston; P Life; D S Kumararatne; H Sharif; J Alexander-Williams; R N Allan
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

Review 8.  Orofacial manifestations of Melkersson-Rosenthal syndrome. A study of 42 patients and review of 220 cases from the literature.

Authors:  W M Zimmer; R S Rogers; C M Reeve; P J Sheridan
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1992-11

9.  Lymphocyte proliferation response to baker's yeast in Crohn's disease.

Authors:  C A Young; A Sonnenberg; E A Burns
Journal:  Digestion       Date:  1994       Impact factor: 3.216

10.  Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS.

Authors:  M M Coogan; S P Sweet; S J Challacombe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more
  4 in total

1.  Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers.

Authors:  Heba S Said; Wataru Suda; Shigeki Nakagome; Hiroshi Chinen; Kenshiro Oshima; Sangwan Kim; Ryosuke Kimura; Atsushi Iraha; Hajime Ishida; Jiro Fujita; Shuhei Mano; Hidetoshi Morita; Taeko Dohi; Hiroki Oota; Masahira Hattori
Journal:  DNA Res       Date:  2013-09-07       Impact factor: 4.458

2.  Immunophenotype in orofacial granulomatosis with and without Crohn's disease.

Authors:  Gita Gale; Sofia Ostman; Robert Saalman; Esbjörn Telemo; Mats Jontell; Bengt Hasséus
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-11-01

Review 3.  Salivary Stress/Immunological Markers in Crohn's Disease and Ulcerative Colitis.

Authors:  Alberto Finamore; Ilaria Peluso; Omar Cauli
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

4.  Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease.

Authors:  Kacper Nijakowski; Rafał Rutkowski; Piotr Eder; Katarzyna Korybalska; Janusz Witowski; Anna Surdacka
Journal:  Life (Basel)       Date:  2021-12-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.